VX-765

Vertex Pharmaceuticals Incorporated · Phase 2 active Small molecule

At a glance

Generic name	VX-765
Sponsor	Vertex Pharmaceuticals Incorporated
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Evaluate the Efficacy and Safety of VX-765 in Subjects With Treatment-Resistant Partial Epilepsy (PHASE2)
Study of VX-765 in Subjects With Treatment-resistant Partial Epilepsy (PHASE2)
Phase 2 Clinical Study in Psoriasis With Oral Investigational Drug VX-765 (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

VX-765 CI brief — competitive landscape report
VX-765 updates RSS · CI watch RSS
Vertex Pharmaceuticals Incorporated portfolio CI